TOP TIERMARKET NEWSWIRE
News & sentiment

OCULAR THERAPEUTIX I (OCUL) — News & AI sentiment

OCULAR THERAPEUTIX I (OCUL) news roundup. 6 stories in the past week, 12 over 30 days. Average 30-day sentiment is 62.2/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 5 sales totalling $333K — net selling of $333K. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →
24h stories
0
7d stories
6
avg sentiment 65.3/100
30d stories
12
avg sentiment 62.2/100
Insider net (90d)
$333K
0 buys · 5 sells
Congress (90d)
0
0 buys · 0 sells

OCUL news in the last 24 hours, 7 days, 30 days and 90 days

How much OCUL coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time windowOCUL storiesAvg AI sentimentRead
Last 24 hours0no coverage
Last 7 days665.3/100OCUL headlines →
Last 30 days1262.2/100OCUL headlines →
Last 90 days3257.5/100OCUL headlines →

Latest stories on OCUL

H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy
Investing.com Analyst Ratings61 · neutralanalyst
1d ago
2d ago
2d ago
2d ago
2d ago
7d ago
Sep 8
Sep 8
Sep 3
Sep 1
Sep 1
Aug 18
Aug 17
Ocular gains on EyePoint phase 3 wet AMD miss
Seeking Alpha38 · neutralgeneral
Aug 17
Why is Ocular Therapeutix stock rallying today?
Investing.com Markets50 · neutralgeneral
Aug 17
Ocular Therapeutix rises 10.4%
The Fly58 · neutralgeneral
Aug 17
Aug 13
Aug 13
Aug 11
Aug 7
Aug 7
Aug 5
Aug 4
Aug 3
Aug 3
Open OCUL in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →